Sevoflurane promotes the apoptosis of laryngeal squamous cell carcinoma in-vitro and inhibits its malignant progression via miR-26a/FOXO1 axis

Abstract

Laryngeal squamous cell carcinoma (LSCC) is a laryngeal malignancy with a high mortality rates, and its treatment remains difficult. Sevoflurane is a surgical anesthesia which has anti-tumor effect. This investigation assessed the effects of LSCC cells treatment with Sevoflurane in vitro and in vivo. Hep-2 and Tu177 cells, human LSCC samples and BALB/C nude mice were used for result assessments. Cell viability, proliferation, migration and invasion were assessed via Cell Count Kit-8, wound healing assay and transwell invasion assay respectively. MiR-26a and FOXO1 expressions was examined by qRT-PCR. FOXO1, E-cadherin, N-cadherin and vimentin activities were examined by Western blotting. Moreover, animal experiments were performed to verify our findings in vitro. Lastly, miR-26a and FOXO1 expression levels in clinical samples were analyzed. According to the results, Sevoflurane decreased LSCC cells' viability and even stimulated their apoptosis in vitro and in vivo. Moreover, it could reduce the migration, invasion and EMT. Mechanistically, sevoflurane could downregulate miR-26a expression and that miR-26a could negatively modulate FOXO1 activity. Thus, sevoflurane could increase FOXO1 activity. In the clinical samples, miR-26a expression was significantly upregulated, but FOXO1 was remarkably down-regulated and miR-26a expression in LSCC was linked with better prognosis. In conclusion, MiR-26a is increased and FOXO1 is reduced in human LSCC, Sevoflurane inhibits proliferation and mediates apoptosis of LSCC cells. Further, MiR-26a binds FOXO1 directly, and FOXO1 expression is down-regulated by Sevoflurane. Finally, Sevoflurane triggers LSCC cells apoptosis in vivo. Sevoflurane use to target miR-26a/FOXO1 may be a novel alternative for LSCC therapy.

Sevoflurane induces inflammation in primary hippocampal neurons by regulating Hoxa5/Gm5106/miR-27b-3p positive feedback loop

“…Sevoflurane is an inhalational anesthetic with common application in surgery. Studies have shown that sevoflurane affects cancer progression and inflammations via mediating signaling pathways and gene expressions [ 7 , 8 ]. It altered pathophysiological situations of brain, which leads to neuroinflammation and results in neurodegenerative changes.…”

Diagnostic and Prognostic Value of microRNAs in Patients with Laryngeal Cancer: A Systematic Review

“…Of those, 166 were excluded for describing HNSCC cases without focus on the larynx ( n = 28), for being exclusively in vitro studies ( n = 39), for having a number of patients less than 10 or for using patient data from public databases ( n = 50), for not quantifying miRNAs in patient samples ( n = 43) and for other reasons, such as for not having statistically significant results or wrong miRNA sequence ( n = 6). Finally, the review was performed on a total of 177 studies [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 …”

“…One miRNA, miR-26a-5p, was described with opposite roles in two studies [ 53 , 108 ]. For this reason, this miRNA was not included in the analysis.…”

Effect of Inhalation Anesthetics on Tumor Metastasis

“…46 Also, sevoflurane promotes the apoptosis of laryngeal squamous cell carcinoma in-vitro and inhibits its malignant progression via miR-26a/FOXO1 axis. 47 In a large number of glioma studies, sevoflurane has shown anti-tumor effects through multiple miRNA pathways, For example, increasing the expression of miR-637, 48 miR-124-3p, 49 miR-34a-5p, 50 miR-146b-5p, 28 miR-210, 51 miR-27b, 52 or miR-144-3p 53 to regulate its corresponding downstream molecules and inhibit the migration and invasion of glioma cells. In addition to directly acting on miRNA, sevoflurane can play a regulatory role by acting on upstream circRNA.…”